FELIMAZOLE- methimazole tablet, sugar coated

Country: United States

Language: English

Source: NLM (National Library of Medicine)

Active ingredient:

methimazole (UNII: 554Z48XN5E) (methimazole - UNII:554Z48XN5E)

Available from:

Dechra Veterinary Products

Administration route:

ORAL

Prescription type:

PRESCRIPTION

Therapeutic indications:

INDICATION: Felimazole Coated Tablets (methimazole tablets) are indicated for the treatment of hyperthyroidism in cats. CONTRAINDICATIONS: Do not use in cats with hypersensitivity to methimazole, carbimazole or the excipient, polyethylene glycol. Do not use in cats with primary liver disease or renal failure. Do not use in cats with autoimmune disease. See ADVERSE REACTIONS. Do not use in cats with hematological disorders (such as anemia, neutropenia, lymphopenia, or thrombocytopenia) or coagulopathies. See ADVERSE REACTIONS. Do not use in pregnant or lactating queens. Laboratory studies in rats and mice have shown evidence of teratogenic and embryotoxic effects of methimazole.

Product summary:

HOW SUPPLIED: Felimazole Coated Tablets are available in 2.5 mg or 5 mg in bottles containing 100 tablets.

Authorization status:

New Animal Drug Application

Summary of Product characteristics

FELIMAZOLE- METHIMAZOLE TABLET, SUGAR COATED
DECHRA VETERINARY PRODUCTS
----------
FELIMAZOLE COATED TABLETS
(METHIMAZOLE TABLETS)
For oral use in cats only
CAUTION:
Federal law restricts this drug to use by or on the order of a
licensed veterinarian.
DESCRIPTION:
Methimazole is a thioureylene antithyroid drug, which inhibits the
synthesis of thyroid
hormones. Methimazole (1-methylimidazole-2-thiol) is a white,
crystalline substance that
is freely soluble in water. The chemical formula is C H N S. Molecular
weight is 114.16.
METHIMAZOLE CHEMICAL STRUCTURE:
INDICATION:
Felimazole Coated Tablets (methimazole tablets) are indicated for the
treatment of
hyperthyroidism in cats.
DOSAGE AND ADMINISTRATION:
The starting dose of Felimazole Coated Tablets is 2.5 mg administered
every 12 hours.
Following 3 weeks of treatment, the dose should be titrated to effect
based on individual
serum total T4 (TT4) levels and clinical response. Dose adjustments
should be made in
2.5 mg increments. The maximum total dosage is 20 mg per day divided,
not to exceed
10 mg as a single administration.
Hematology, biochemistry, and TT4 should be evaluated prior to
initiating treatment and
monitored after 3 weeks and 6 weeks of treatment. Thereafter,
bloodwork should be
monitored every 3 months and the dose adjusted as necessary. Cats
receiving doses
greater than 10 mg per day should be monitored more frequently.
CONTRAINDICATIONS:
Do not use in cats with hypersensitivity to methimazole, carbimazole
or the excipient,
polyethylene glycol.
®
4
6
2
Do not use in cats with primary liver disease or renal failure.
Do not use in cats with autoimmune disease. See ADVERSE REACTIONS.
Do not use in cats with hematological disorders (such as anemia,
neutropenia,
lymphopenia, or thrombocytopenia) or coagulopathies. See ADVERSE
REACTIONS.
Do not use in pregnant or lactating queens. Laboratory studies in rats
and mice have
shown evidence of teratogenic and embryotoxic effects of methimazole.
WARNINGS:
Methimazole has anti-vitamin K activity and may induce b